RELIEF THERAPEUTICS HOLDING SA forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to fund our various product candidate development programs and to meet our business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by our intellectual property, the substantial costs and diversion of management's attention and resources which could result from pending securities litigation, risks related to the drug development and the regulatory approval process, including the timing and requirements of regulatory actions, and the impact of competitive products and technological changes. We disclaim any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. You should review additional disclosures we make in our filings with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K. You may access these documents for no charge at http://www.sec.gov. RELIEF FORWARD-LOOKING STATEMENTS This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its businesses. The results reported herein may or may not be indicative of the results of future and larger clinical trials for ACER-001 for the treatment of UCDs and MSUD, nor whether the ongoing clinical trials of Relief's lead compound, RLF-100(TM) (aviptadil) in advanced clinical development to treat respiratory deficiency due to COVID-19, will be successful. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. CORPORATE CONTACTS Acer Therapeutics: Jim DeNike Acer Therapeutics Inc. jdenike@acertx.com +1 844-902-6100 RELIEF THERAPEUTICS Holding AG: Jack Weinstein Chief Financial Officer and Treasurer contact@relieftherapeutics.com MEDIA CONTACTS Relief (Europe): Anne Hennecke MC Services AG relief@mc-services.eu +49 (0) 211-529-252-22 INVESTOR RELATIONS CONTACTS Relief (Europe): Anne Hennecke MC Services AG relief@mc-services.eu +49 (0) 211-529-252-22 Acer Therapeutics: Hans Vitzthum LifeSci Advisors hans@lifesciadvisors.com +1 617-430-7578 =---------------------------------------------------------------------------------------------------------------------- End of Media Release =---------------------------------------------------------------------------------------------------------------------- Language: English Company: RELIEF THERAPEUTICS Holdings AG Avenue de Sécheron 15 1202 Genève Switzerland E-mail: contact@relieftherapeutics.com Internet: https://relieftherapeutics.com ISIN: CH0100191136 Listed: SIX Swiss Exchange EQS News ID: 1199957 End of News EQS Group News Service =------------
1199957 2021-05-25
Image link:
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1199957&application_name=news(END) Dow Jones Newswires
May 25, 2021 01:01 ET (05:01 GMT)
